MannKind Corporation has announced the resignation of Alfred Mann as Executive Chairman and the appointment of Kent Kresa as Chairman of the Board, effective immediately. Mann will continue as a non-executive advisor, the company said. Kresa is Chairman Emeritus of Northrop Grumman Corporation and has served on the boards of numerous companies, universities, and … [Read more...] about Kent Kresa takes over as MannKind’s Chairman of the Board
News
Japanese authorities approve Phase 2/3 trial of inhaled molgramostim
Serendex Pharmaceuticals has announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved the company's planned IMPALA Phase 2/3 clinical trial of Molgradex inhaled molgramostim for pulmonary alveolar proteinosis (PAP). According to the company, the trial has already been approved in Denmark and the Netherlands, and will also include … [Read more...] about Japanese authorities approve Phase 2/3 trial of inhaled molgramostim
Capsugel teams up with Pulmatrix on DPI development
Capsugel and Pulmatrix have announced an agreement for development of new inhaled therapies based on the spray drying and manufacturing expertise at Capsugel's Bend Research subsidiary combined with Pulmatrix's iSPERSE dry powder technology. Bend Research Head of Alliance Strategy Dan Dobry commented, “This strategic partnership with Pulmatrix puts our companies … [Read more...] about Capsugel teams up with Pulmatrix on DPI development
Positive Phase 2b results for Ockham’s inhaled heparin for COPD
UK-based Ockham Biotech has announced that data from a Phase 2b study of its inhaled heparin for the treatment of COPD demonstrate significant improvement in lung function compared to placebo, with improvements maintained for 7 days after cessation of treatment and no adverse events. The study involved 24 moderate-to-severe COPD patients who received either … [Read more...] about Positive Phase 2b results for Ockham’s inhaled heparin for COPD
Meda to be acquired by Mylan
Mylan has announced that it will acquire Meda, which markets a number of OINDPs, including Dymista, Astelin, and Astepro nasal sprays; the Aerospan MDI; and the Novopulmon Novolizer and Formatris Novolizer DPIs. Meda had previously rejected acquisition by Mylan, but the Meda board now recommends that shareholders accept the offer, which is valued at SEK 60.3 billion … [Read more...] about Meda to be acquired by Mylan
Medical Developments International acquires Breath-A-Tech
Australian device company Medical Developments International (MVP) has acquired Australian spacer company Breath-A-Tech from Avita Medical for A$2.47 million, comprised of A$2.029 million cash up front and 117,894 shares of MVP stock, which will be escrowed for 6 months, the company said. Breath-A-Tech's products include the Breath-A-Tech spacer and the Funhaler … [Read more...] about Medical Developments International acquires Breath-A-Tech
Fraunhofer ITEM acquires Takeda inhaled surfactant technology
The Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) has acquired Takeda's Surfactant and Continuous Powder Aerosolization (CPA) program, the company said. According to the announcement, the transfer took place as Takeda shut down its respiratory department; Takeda sold its core respiratory business to AstraZeneca in December 2015. According … [Read more...] about Fraunhofer ITEM acquires Takeda inhaled surfactant technology
Cirrus Pharmaceuticals announces new inhaler manufacturing services
CDMO Cirrus Pharmaceuticals, a subsidiary of Kemwell, has announced the availability of cGMP inhaler manufacturing services for early phase clinical trials materials at its new facility in Raleigh-Durham, NC. Cirrus announced in October 2014 that it was investing in a new manufacturing suite for a variety of dosage forms, including OINDPs. Cirrus VP of R&D Andrew … [Read more...] about Cirrus Pharmaceuticals announces new inhaler manufacturing services
Rhinocort nasal spray now available over the counter in the US
Johnson & Johnson subsidiary McNeil Consumer Healthcare says that Rhinocort budesonide nasal spray is now available over the counter in the US for the treatment of allergic rhinitis. McNeil acquired the OTC rights to AstraZeneca's Rhinocort Aqua in 2014. McNeil Consumer Healthcare Group Brand Director Purvi Farahi commented, “For consumers who are suffering from … [Read more...] about Rhinocort nasal spray now available over the counter in the US
Septodont to promote Egalet’s Sprix nasal spray to US dentists
Egalet Corporation has announced that it has partnered with Septodont, Inc. to promote Sprix ketorolac tromethamine nasal spray to US dentists. Septodont will pay Egalet an undisclosed licensing fee up front, sales-based milestones and a share of profits from net sales. Sprix was approved by the FDA in 2010 for short-term treatment of moderate-to-severe pain. Its … [Read more...] about Septodont to promote Egalet’s Sprix nasal spray to US dentists